Concepedia

Morbidity associated with the use of oxaliplatin versus mitomycin C in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal or appendiceal origin: a multi-institutional comparative study

Ella Benzaquen, Yifan Wang, Stephanie Wiseman, V. Rosenfeld, Lucas Sidéris, Pierre Dubé, Jean‐Sébastien Pelletier, Tsafrir Vanounou

Canadian Journal of Surgery · 2021 · 13 citations · 20 references

DOIFull text

Open access

Abstract

MMC and oxaliplatin are both suitable agents for HIPEC and are associated with comparable morbidity and toxicity profiles, regardless of cancer origin. Thus, we propose that cost-effectiveness should ultimately dictate drug selection.

References

20

A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation

Mary E. Charlson, Peter Pompei, Kathy L. Aleš et al. · Journal of Chronic Diseases · 1987 · 48.8K citations

, , +11

The Clavien-Dindo Classification of Surgical Complications

Pierre A. Clavien, Jeffrey Barkun, Michelle Oliveira et al. · Annals of Surgery · 2009 · 10.9K citations

What Is Value in Health Care?

Michael E. Porter · New England Journal of Medicine · 2010 · 4.7K citations

, , +21

Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients With Peritoneal Carcinomatosis of Colorectal Cancer

Victor J. Verwaal, Serge van Ruth, Eelco de Bree et al. · Journal of Clinical Oncology · 2003 · 2K citations

Appendiceal Neoplasms With Peritoneal Dissemination: Outcomes After Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy

John H. Stewart, Perry Shen, Gregory B. Russell et al. · Annals of Surgical Oncology · 2006 · 168 citations

, , +8